Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy.

"normalized and batch corrected ct values (appendix 1) and dea results (appendix 2) are openly available at doi 10 5281/zenodo 10223492."

"Conflict of interest RM is employee at SSI that developed the H56:IC31 vaccine. He is not inventor of related patents and have no personal financial interests. IC31 is a trademark of Valneva Austria GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was funded by The Research Council of Norway (RCN, GlobVac no 234493), Oslo University Hospital, Norway, the University of Oslo, Norway, and Statens Serum Institut, Denmark."